Study #2025-1557
A phase 2 study of radiotherapy-induced immune priming to enhance Elranatamab (Elra) in relapsed refractory multiple myeloma (RRMM) with extramedullary disease (EMD) and paramedullary disease (PMD) "PRIME-EMD-PMD"
MD Anderson Study Status
Enrolling
Treatment Agent
Elranatamab
Description
To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Phase 2, Radiotherapy-Induced Immune Priming, Elranatamab, Relapsed Refractory Multiple Myeloma (RRMM), Extramedullary Disease in Multiple Myeloma, Paramedullary Disease, PMD
Study phase:
Phase II
Physician name:
Jing Ye
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?